RESUMEN
Despite advancement in medical care, Rh alloimmunisation remains a major cause of neonatal hyperbilirubinaemia, neuro-morbidity, and late-onset anaemia. Delayed cord clamping (DCC), a standard care now-a-days, is yet not performed in Rh-alloimmunised infants due to paucity of evidence. Hence, we randomised these infants of 28- to 41-week gestation to delayed cord clamping (N = 36) or early cord clamping (N = 34) groups. The primary outcome variable was venous packed cell volume (PCV) at 2 h of birth. The secondary outcomes were incidence of double volume exchange transfusion (DVET) and partial exchange transfusion (PET), duration of phototherapy (PT), functional echocardiography (parameters measured: superior vena cava flow, M-mode fractional shortening, left ventricular output, myocardial perfusion index, and inferior vena cava collapsibility) during hospital stay, and blood transfusion (BT) until 14 weeks of life. Neonates were managed as per unit protocol. The baseline characteristics of enrolled infants were comparable between the groups. The median (IQR) gestation and mean (SD) birth weight of enrolled infants were 35 (33-37) weeks and 2440 (542) g, respectively. The DCC group had a higher mean PCV at 2 h of life (48.4 ± 9.2 vs. 43.5 ± 8.7, mean difference 4.9% (95% CI 0.6-9.1), p = 0.03). However, incidence of DVET and PET, duration of PT, echocardiography parameters, and BT until 14 weeks of postnatal age were similar between the groups.Conclusion: DCC in Rh-alloimmunised infants improved PCV at 2 h of age without significant adverse effects.Trial registration: Clinical Trial Registry of India (CTRI), Ref/2016/11/012572 http://ctri.nic.in/Clinicaltrials, date of trial registration 19.12.2016, date of first patient enrolment 1 January 2017.What is Known:â¢Delayed cord clamping improves haematocrit, results in better haemodynamic stability, and decreases the need of transfusion in early infancy.â¢However, due to lack of evidence, potential risk of hyperbilirubinaemia, and exacerbation of anaemia (following delayed cord clamping), early cord clamping is the usual norm in Rh-alloimmunised infantsinfants.What is New:â¢Delayed cord clamping in Rh-alloimmunised infants improves haematocrit at 2 h of life without any increase in incidence of serious adverse effects.
Asunto(s)
Eritroblastosis Fetal/prevención & control , Hiperbilirrubinemia Neonatal/prevención & control , Atención Perinatal/métodos , Isoinmunización Rh/terapia , Cordón Umbilical , Constricción , Eritroblastosis Fetal/etiología , Femenino , Estudios de Seguimiento , Hematócrito , Humanos , Hiperbilirrubinemia Neonatal/etiología , Recién Nacido , Masculino , Isoinmunización Rh/complicaciones , Método Simple Ciego , Factores de Tiempo , Resultado del TratamientoRESUMEN
Intrauterine transfusion is one of the mainstays of treatment in isoimmunised pregnancies guided by the changes in middle cerebral artery Doppler of the fetus. The common postnatal complications associated with Rh isoimmunisation are high unconjugated bilirubin requiring blood exchange transfusions, cholestasis due to bile inspissation, thrombocytopenia and anaemia. Hyperferritinaemia is an uncommon adverse effect observed in Rh isoimmunised pregnancies. In this case report, we describe the clinical course of a Rh isoimmunised neonate with hyperferritinaemia and transfusion acquired cytomegalovirus disease which resolved. Iron chelation therapy was not necessary.
Asunto(s)
Transfusión de Sangre Intrauterina/efectos adversos , Insuficiencia de Crecimiento/terapia , Sobrecarga de Hierro/diagnóstico , Fototerapia/métodos , Complicaciones Hematológicas del Embarazo/terapia , Isoinmunización Rh/terapia , Adulto , Antivirales/uso terapéutico , Bilirrubina/sangre , Velocidad del Flujo Sanguíneo , Transfusión de Sangre Intrauterina/métodos , Insuficiencia de Crecimiento/fisiopatología , Femenino , Ferritinas/sangre , Humanos , Recién Nacido , Sobrecarga de Hierro/fisiopatología , Sobrecarga de Hierro/terapia , Arteria Cerebral Media , Embarazo , Complicaciones Hematológicas del Embarazo/fisiopatología , Isoinmunización Rh/complicaciones , Isoinmunización Rh/fisiopatología , Resultado del Tratamiento , Valganciclovir/uso terapéuticoRESUMEN
A term male infant was admitted at 48 h of postnatal life to the neonatal unit for jaundice. The investigation showed total serum bilirubin (TSB) of 17.1 mg/dl, haemoglobin of 11 g/dl, reticulocyte count of 9.5% and peripheral smear was suggestive of macrocytic, normochromic red blood cell (RBC) with target cells and multiple spherocytes with occasional nucleated RBC. The infant's blood group was B positive. Direct antiglobulin test was strongly positive by gel method (3+). Mother's blood group was B positive and indirect antiglobulin test was positive when tested postnatally. Extended minor blood grouping and cross matching showed this as a case of combined anti e and anti C antibodies isoimmunisation. Infant was treated with phototherapy for 72 h and was shifted to mother side. Infant was serially monitored with TSB level every sixth hourly and American Academy of Pediatrics (AAP) phototherapy charts were followed to see for rebound hyperbilirubinemia. The neonate was discharged and there was no readmission for hyperbilirubinemia. It is very rare and we report the third case of its type till date.
Asunto(s)
Hiperbilirrubinemia Neonatal/inmunología , Isoinmunización Rh/complicaciones , Humanos , Recién Nacido , Masculino , Isoinmunización Rh/inmunologíaRESUMEN
Khdair-Ahmad F, Aladily T, Khdair-Ahmad O, Badran EF. Chelation therapy for secondary neonatal iron overload: Lessons learned from rhesus hemolytic disease. Turk J Pediatr 2018; 60: 335-339. Secondary neonatal iron overload occurs with intrauterine and post-natal blood transfusions. Treatment with intravenous Deferoxamine was reported only in four cases in the literature. Herein we report a case of a patient born at 36 weeks of gestation, who had rhesus hemolytic disease. He developed secondary iron overload, causing liver injury, after a total of six blood transfusions: four intrauterine and 2 post-natal transfusion therapies. Intravenous Deferoxamine treatment was started at the age of 45 days due to a ferritin level of 40,000 mg/L, progressive rise of liver enzymes, and worsening cholestasis. Treatment resulted in marked reduction in ferritin level (down to 829 mg/L at the age of 6 months), significant improvement in the liver enzymes, and resolution of cholestasis.
Asunto(s)
Terapia por Quelación/métodos , Deferoxamina/uso terapéutico , Eritroblastosis Fetal/terapia , Sobrecarga de Hierro/tratamiento farmacológico , Isoinmunización Rh/complicaciones , Transfusión Sanguínea , Colestasis/etiología , Femenino , Ferritinas/sangre , Humanos , Lactante , Recién Nacido , Sobrecarga de Hierro/etiología , Hígado/patología , Masculino , Embarazo , Isoinmunización Rh/terapiaRESUMEN
BACKGROUND: Individuals with the partial D phenotype when exposed to D+ red blood cells (RBCs) carrying the epitopes they lack may develop anti-D specific for the missing epitopes. DNB is the most common partial D in Caucasians and the clinical significance for anti-D in these individuals is unknown. STUDY DESIGN AND METHODS: This article describes the serologic genotyping results and clinical manifestations in two group D+ babies of a mother presenting as group O, D+ with alloanti-D. RESULTS: The mother was hemizygous for RHD*DNB gene and sequencing confirmed a single-nucleotide change at c.1063G>A. One baby (group A, D+) displayed bilirubinemia at birth with a normal hemoglobin level. Anti-A and anti-D were eluted from the RBCs. For the next ongoing pregnancy, the anti-D titer increased from 32 to 256. On delivery the baby typed group O and anti-D was eluted from the RBCs. This baby at birth exhibited anemia, reticulocytosis, and hyperbilirubinemia requiring intensive phototherapy treatment from Day 0 to Day 9 after birth and was discharged on Day 13. Intravenous immunoglobulin was also administered. Both babies were heterozygous for RHD and RHD*DNB. CONCLUSION: The anti-D produced by this woman with partial D DNB resulted in a case of hemolytic disease of the fetus and newborn (HDFN) requiring intensive treatment in the perinatal period. Anti-D formed by women with the partial D DNB phenotype has the potential to cause HDFN where the fetus is D+. Women carrying RHD*DNB should be offered appropriate prophylactic anti-D and be transfused with D- RBCs if not already alloimmunized.
Asunto(s)
Eritroblastosis Fetal/sangre , Isoinmunización Rh/complicaciones , Globulina Inmune rho(D)/efectos adversos , Sistema del Grupo Sanguíneo ABO/sangre , Análisis Mutacional de ADN , Eritroblastosis Fetal/patología , Eritroblastosis Fetal/terapia , Femenino , Enfermedades Fetales , Feto , Genotipo , Humanos , Recién Nacido , Madres , Polimorfismo de Nucleótido Simple , Embarazo , Sistema del Grupo Sanguíneo Rh-Hr/sangreRESUMEN
UNLABELLED: Rh-isoimmunization is a pathological condition in which the fetal red blood cells of a Rh (+) fetus are destroyed by the isoantibodies of a Rh (-) woman sensitized in a previous event. Despite of the wide spread implementation of anti D-gammaglobolin prophylaxis this is still the most common cause for fetal anemia. Recently, sonographic measurement of the fetal middle cerebral artery peak systolic velocity (MCA-PSV) has been shown to be an accurate non-invasive test to predict low fetal hemoglobin levels. We present a case report of Rh-alloimmunized pregnancy with moderate fetal anemia, followed-up by weekly MCA-PSV measurements. CASE REPORT: A 37-year-old Rh (-) negative gravida 3, para 1, without anti-D gammaglobolin prophylaxis in her previous pregnancies, presented at 27+0 weeks of gestation (w.g.) for a routine third trimester scan. Subsequent ultrasound measurements of MCA-PSV confirmed a progressive increase of the peak systolic velocities from 40 to 80 cm/sec, as well as a gradual rise in the anti-D titers. The evidence of developing fetal anemia necessitated elective Caesarean section performed at 35 wg. The neonate was admitted in the intensive care unit and required resuscitation, one exchange blood transfusion and several courses of phototherapy. The patient was discharged two weeks post partum. CONCLUSIONS: There is a strong correlation between the high peak systolic velocities in the middle cerebral artery (MCA-PSV) and the low levels of fetal hemoglobin. The high sensitivity and positive predictive value concerning the development of fetal anemia, as well as its good repeatability, makes this non-invasive test a valuable asset in the management of all pregnancies complicated by severe Rh-alloimmunization.
Asunto(s)
Anemia Neonatal/diagnóstico , Anemia Neonatal/terapia , Enfermedades Fetales/diagnóstico , Arteria Cerebral Media/fisiopatología , Isoinmunización Rh/complicaciones , Adulto , Anemia Neonatal/diagnóstico por imagen , Anemia Neonatal/etiología , Transfusión Sanguínea , Femenino , Enfermedades Fetales/diagnóstico por imagen , Enfermedades Fetales/etiología , Humanos , Recién Nacido , Arteria Cerebral Media/diagnóstico por imagen , Fototerapia , Embarazo , Pronóstico , Ultrasonografía PrenatalAsunto(s)
Antígenos de Grupos Sanguíneos/análisis , Eritroblastosis Fetal , Hiperbilirrubinemia Neonatal , Fototerapia/métodos , Isoinmunización Rh , Sistema del Grupo Sanguíneo Rh-Hr/sangre , Eritroblastosis Fetal/sangre , Eritroblastosis Fetal/etiología , Humanos , Hiperbilirrubinemia Neonatal/sangre , Hiperbilirrubinemia Neonatal/etiología , Hiperbilirrubinemia Neonatal/fisiopatología , Hiperbilirrubinemia Neonatal/terapia , Recién Nacido , Masculino , Isoinmunización Rh/sangre , Isoinmunización Rh/complicaciones , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
ABO iso-immunization is the most frequent haemolytic disease of the newborn. Treatment depends on the total serum bilirubin level, which may increase very rapidly in the first 48 hours of life in cases of haemolytic disease of the newborn. Phototherapy and, in severe cases, exchange transfusion are used to prevent hyperbilirubinaemic encephalopathy. Intravenous immunoglobulins (IVIG) are used to reduce exchange transfusion. Herein, we present a female newborn who was admitted to the NICU because of ABO immune haemolytic disease. After two courses of 1 g/kg of IVIG infusion, she developed necrotizing enterocolitis (NEC). Administration of IVIG to newborns with significant hyperbilirubinaemia due to ABO haemolytic disease should be cautiously administered and followed for complications.
Asunto(s)
Sistema del Grupo Sanguíneo ABO , Enterocolitis Necrotizante/etiología , Hiperbilirrubinemia Neonatal/terapia , Inmunoglobulinas Intravenosas/efectos adversos , Factores Inmunológicos/efectos adversos , Isoinmunización Rh/complicaciones , Femenino , Humanos , Hiperbilirrubinemia Neonatal/complicaciones , Inmunoglobulinas Intravenosas/administración & dosificación , Factores Inmunológicos/administración & dosificación , Recién Nacido , Fototerapia , Isoinmunización Rh/terapia , Resultado del TratamientoRESUMEN
BACKGROUND: Neonates with Rhesus c (Rh c) hemolytic disease of the fetus and newborn (HDFN) are often managed in the same way as neonates with Rhesus D (Rh D) HDFN, although evidence to support this policy is limited. The objective of this study was to evaluate neonatal outcome in severe Rh c HDFN compared to Rh D HDFN. STUDY DESIGN AND METHODS: A retrospective study of (near-)term neonates with severe Rh c (n = 22) and Rh D HDFN (n = 103; without additional antibodies) admitted to the Leiden University Medical Center between January 2000 and October 2011 was conducted. The need for intrauterine transfusions (IUTs), phototherapy, exchange transfusions (ETs), and top-up transfusions up to 3 months of age were recorded and compared between both groups. RESULTS: Although there was a trend for a slightly more severe antenatal course for Rh D HDFN reflected by an earlier need for and higher number of IUTs (median [interquartile range], 2 [1.5-4] vs. 2 [1-2] in Rh c HDFN; p = 0.070), no significant differences were found for the postnatal course between Rh c and Rh D group in days of phototherapy (mean, Days 4.8 and 4.6, respectively; p = 0.569), need for ET (50% vs. 44%, respectively; p = 0.589), and top-up transfusions (62% vs. 78%, respectively; p = 0.128). CONCLUSION: Postnatal outcome in neonates with severe Rh c HDFN is similar compared to neonates with severe Rh D hemolytic disease in terms of days of phototherapy, need for ET, and need for top-up transfusions. These results justify a similar postnatal management of neonates with Rh D and Rh c HDFN.
Asunto(s)
Eritroblastosis Fetal/etiología , Isoinmunización Rh/complicaciones , Sistema del Grupo Sanguíneo Rh-Hr/inmunología , Transfusión de Sangre Intrauterina , Eritroblastosis Fetal/terapia , Recambio Total de Sangre , Humanos , Recién Nacido , Isoanticuerpos/sangre , Fototerapia , Estudios Retrospectivos , Globulina Inmune rho(D)RESUMEN
Rh isoimmunisation leads to haemolytic anaemia and hyperbilirubinaemia in the first h of life. Isolated early onset neonatal anaemia has rarely been reported. The authors describe the case of a term infant, born to an 'A' negative, second gravida mother. On the second day of life, pallor was noticed. His haemoglobin (Hb) was 6.8 g/dl, he had reticulocytosis and a positive direct antiglobulin test. However, he did not have a high total serum bilirubin (TSB) (87.2 µmol/l). He was transfused with red blood cells and kept under phototherapy for 3 days. Three weeks later, he received another transfusion for severe anaemia (Hb 6 5 g/dl). During this period, he was never jaundiced and the maximum level of TSB was 122 µmol/l. On follow-up, his Hb stabilised and he had no further problems. This report highlights the possibility of early onset anaemia without jaundice as the sole manifestation of Rh isoimmunisation.
Asunto(s)
Anemia Macrocítica/etiología , Enfermedades del Recién Nacido/etiología , Isoinmunización Rh/complicaciones , Anemia Macrocítica/inmunología , Anemia Macrocítica/terapia , Bilirrubina/sangre , Transfusión de Eritrocitos , Ácido Fólico/uso terapéutico , Hemoglobinas/análisis , Humanos , Recién Nacido , Enfermedades del Recién Nacido/inmunología , Enfermedades del Recién Nacido/terapia , Masculino , Fototerapia , Isoinmunización Rh/inmunología , Isoinmunización Rh/terapiaRESUMEN
OBJECTIVE: To evaluate neonatal outcomes among a homogeneous group of fetuses with severe hydrops treated with intrauterine transfusion (IUT). METHODS: In a prospective study at Dokuz Eylul University School of Medicine, Izmir, Turkey, outcomes were compared for 35 IUTs carried out between 2005 and 2010 in 19 pregnancies that were complicated by Rhesus D hemolytic disease with severely hydropic fetuses. RESULTS: There was no correlation between the number of IUTs and the duration of phototherapy or number of exchange transfusions. After delivery, 36% (7/19) of neonates tested positive in a direct Coombs test and their requirement for exchange transfusion was higher than that of neonates who tested negative. The neonatal survival rate was 73.7%. Admission to the neonatal intensive care unit was 78%, and the median duration of neonatal unit stay was 4 days (range, 1-77 days). Only 1 newborn had hearing impairment. CONCLUSION: IUT is a unique, gold standard treatment for severely hydropic fetuses. When treated optimally with IUT, fetuses with severe hydrops showed no increased risk of neurodevelopmental abnormalities. Factors affecting the survival of hydropic fetuses after IUT, and whether the number of IUTs performed affects the number of exchange transfusions required remain unclear.
Asunto(s)
Transfusión de Sangre Intrauterina/métodos , Hidropesía Fetal/terapia , Fototerapia/métodos , Isoinmunización Rh/complicaciones , Femenino , Humanos , Hidropesía Fetal/fisiopatología , Recién Nacido , Unidades de Cuidado Intensivo Neonatal , Tiempo de Internación , Embarazo , Estudios Prospectivos , Índice de Severidad de la Enfermedad , Tasa de Supervivencia , Resultado del Tratamiento , TurquíaRESUMEN
A term baby with severe BO isoimmunization was treated with intravenous immunoglobulin. Shortly after the completion of the infusion, the baby developed clinical and radiological signs of necrotizing enterocolitis, with intestinal perforation and massive hemorrhagic ascites, resulting in the death of the baby.
Asunto(s)
Sistema del Grupo Sanguíneo ABO , Enterocolitis Necrotizante/etiología , Inmunoglobulinas Intravenosas/efectos adversos , Isoinmunización Rh/complicaciones , Resultado Fatal , Femenino , Humanos , Recién Nacido , Fototerapia , Isoinmunización Rh/terapiaRESUMEN
Neonatal jaundice resulting from immunological hemolysis is not uncommon. While it is possible to prevent a large number of Rh-isoimmune hemolytic diseases by administration of specific anti-D immunoglobulins to the mother, the prevention of incompatibility in the ABO groups is not feasible. In spite of advances made in the use of phototherapy, and in order to avoid kernicterus, the treatment of these jaundices can require one or several exchange transfusions (ET), a therapy which is not devoid of risk. For some time now, the data concerning the efficiency of high-dose intravenous immunoglobulin therapy (HDIIT) in the treatment of these jaundices have been increasing. A review of the literature shows that, if used as soon as possible in newborn infants over 32 weeks of gestation age, afflicted with Rh or ABO hemolytic disease, the HDIIT brings about, with no undesirable side effects, a significant decrease in the ET number as well as a significant reduction in the length of phototherapy and hospitalization. The data suggesting that HDIIT could increase the risk of late transfusion is open to controversy.
Asunto(s)
Anemia Hemolítica Autoinmune/tratamiento farmacológico , Inmunoglobulinas Intravenosas/uso terapéutico , Factores Inmunológicos/uso terapéutico , Ictericia Neonatal/tratamiento farmacológico , Isoinmunización Rh/complicaciones , Isoinmunización Rh/tratamiento farmacológico , Anemia Hemolítica Autoinmune/inmunología , Eritroblastosis Fetal/tratamiento farmacológico , Medicina Basada en la Evidencia , Humanos , Recién Nacido , Ictericia Neonatal/inmunología , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del TratamientoRESUMEN
AIM: To describe a series of patients who received intravenous immunoglobulin (IVIg) for the treatment of neonatal hyperbilirubinaemia and developed necrotizing enterocolitis (NEC) shortly thereafter. POPULATION AND RESULTS: We describe three healthy breastfed newly born infants with isoimmunization-derived hyperbilirubinaemia refractory to phototherapy who were treated with IVIg. Shortly after the perfusion finished they developed clinical and radiological signs compatible with NEC and needed antibiotic therapy, prolonged parenteral nutrition and even surgery in one case. Other conditions such as septicaemia or coagulopathy were ruled out. Microscopic examination of the resected intestine revealed the presence of disseminated thrombi obstructing multiple minor vessels of the mesenteric circulation. CONCLUSION: IVIg in the newborn period should be cautiously employed and always administered under strict medical control.
Asunto(s)
Enterocolitis Necrotizante/etiología , Hiperbilirrubinemia Neonatal/terapia , Inmunoglobulinas Intravenosas/efectos adversos , Dolor Abdominal/diagnóstico por imagen , Antibacterianos/uso terapéutico , Lactancia Materna , Diagnóstico Diferencial , Enterocolitis Necrotizante/terapia , Femenino , Humanos , Hiperbilirrubinemia Neonatal/complicaciones , Inmunoglobulinas Intravenosas/administración & dosificación , Recién Nacido , Masculino , Nutrición Parenteral , Fototerapia , Radiografía , Isoinmunización Rh/complicacionesRESUMEN
Rhesus haemolytic disease of the newborn can lead to complications such as hyperbilirubinaemia, kernicterus and anaemia. Postnatal management consists mainly of intensive phototherapy, exchange transfusion and blood transfusion. During the last decades, significant progress in prenatal care strategies for patients with Rhesus haemolytic disease has occurred. New prenatal management options have led to a remarkable reduction in perinatal mortality. As a result of the increase in perinatal survival, attention is now shifting towards short-term and long-term morbidity. This review focuses on the management of neonatal and paediatric complications associated with Rhesus haemolytic disease, discusses postnatal treatment options and summarizes the results of studies on short-term and long-term outcome.
Asunto(s)
Isoinmunización Rh/complicaciones , Isoinmunización Rh/terapia , Albúminas/uso terapéutico , Anemia Neonatal/complicaciones , Anemia Neonatal/terapia , Colestasis/complicaciones , Fluidoterapia , Humanos , Hidropesía Fetal , Hiperbilirrubinemia Neonatal/etiología , Hiperbilirrubinemia Neonatal/terapia , Inmunoglobulinas Intravenosas/uso terapéutico , Recién Nacido , Kernicterus/etiología , Kernicterus/prevención & control , Metaloporfirinas/uso terapéutico , Fenobarbital/uso terapéutico , Fototerapia , Trombocitopenia/complicacionesRESUMEN
BACKGROUND: Neonates from isoimmunized pregnancies have increased morbidity from neonatal jaundice. The increased bilirubin from haemolysis often needs phototherapy, exchange transfusion or both after birth. Various trials in pregnant women who were not isoimmunized but had other risk factors for neonatal jaundice have shown a reduction in need for phototherapy and exchange transfusion by the use of antenatal phenobarbital. A recent retrospective case-controlled study showed reduction in the need for exchange transfusion for the neonates from isoimmunized pregnancies. OBJECTIVES: To assess the effects of antenatal phenobarbital in red cell isoimmunized pregnancies in reducing the incidence of phototherapy and exchange transfusion for the neonate. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2006). SELECTION CRITERIA: Randomised and quasi-randomised controlled trials of pregnant women established to have red cell isoimmunization in the current pregnancy during their antenatal testing and given phenobarbital alone or in combination with other drugs before birth. DATA COLLECTION AND ANALYSIS: All three review authors independently assessed study eligibility and quality. MAIN RESULTS: No trials met the inclusion criteria for this review. AUTHORS' CONCLUSIONS: The use of antenatal phenobarbital to reduce neonatal jaundice in red cell isoimmunized pregnant women has not been evaluated in randomised controlled trials.
Asunto(s)
Antagonistas de Aminoácidos Excitadores/administración & dosificación , Ictericia Neonatal/prevención & control , Fenobarbital/administración & dosificación , Atención Prenatal/métodos , Isoinmunización Rh/complicaciones , Femenino , Humanos , Recién Nacido , Ictericia Neonatal/etiología , EmbarazoRESUMEN
Jaundice caused by hemolysis continues to challenge practitioners caring for infants in the NICU. Bilirubin levels can rise quickly in the first days of life, and interventions must be prompt to prevent side effects related to hyperbilirubinemia. Conventional treatments such as hydration and phototherapy are common, but new studies suggest that use of intravenous immunoglobin (IVIG) as an additional treatment may prevent the need for exchange transfusion in some babies. This article presents a case study of an infant with blood-type incompatibility treated successfully with multiple doses of IVIG, discusses the pathophysiology and clinical presentation of hemolytic jaundice, and reviews current management strategies for this disease.
Asunto(s)
Eritroblastosis Fetal/terapia , Inmunoglobulinas Intravenosas/uso terapéutico , Factores Inmunológicos/uso terapéutico , Sistema del Grupo Sanguíneo ABO , Adulto , Bilirrubina/sangre , Incompatibilidad de Grupos Sanguíneos/complicaciones , Protocolos Clínicos , Monitoreo de Drogas , Eritroblastosis Fetal/sangre , Eritroblastosis Fetal/etiología , Recambio Total de Sangre , Femenino , Hematócrito , Humanos , Recién Nacido , Infusiones Intravenosas , Ictericia Neonatal/etiología , Metaloporfirinas/uso terapéutico , Enfermería Neonatal , Rol de la Enfermera , Fototerapia , Embarazo , Isoinmunización Rh/complicacionesRESUMEN
Hematologic causes of hydrops fetalis include homozygous alpha-thalassemia and immune hemolytic anemias. We report the case of a boy with hydrops fetalis who had homozygous alpha-thalassemia and alloimmune hemolytic anemia due to anti-E and anti-C blood group antibodies. He received intrauterine red blood cell transfusions and postnatal chronic transfusion with iron chelation therapy. A non-myeloablative sibling stem cell transplant failed. He is now 5 years and 6 months of age, hypothyroid with short stature, but in overall good health. He is one of the oldest reported homozygous alpha-thalassemia survivors and, to our knowledge, the only survivor with immune- and nonimmune-induced hydrops fetalis.
Asunto(s)
Hidropesía Fetal/etiología , Isoinmunización Rh/complicaciones , Talasemia alfa/complicaciones , Adulto , Preescolar , Femenino , Homocigoto , Humanos , Hidropesía Fetal/genética , Hidropesía Fetal/inmunología , Recién Nacido , Masculino , Isoinmunización Rh/genética , Isoinmunización Rh/inmunología , Sobrevivientes , Talasemia alfa/genética , Talasemia alfa/inmunologíaRESUMEN
Rhesus (Rh) isoimmunization presenting as severe neonatal hemolytic disease is rare in RhD negative primigravidas of Chinese ethnicity. We report the case of a 32-year-old pregnant Taiwanese woman, RhD negative, who gave birth vaginally to two RhD-positive full-term fetuses 6 years apart. Antenatal follow-up was uneventful and there was no obvious fetal-maternal hemorrhage except at the performance of amniocentesis at the 19th week of the first pregnancy without anti-D immune globulin prophylaxis. Although anti-D immune globulins were administered to the mother within 1 hour after each birth, both of the newborns had severe neonatal hemolysis refractory to phototherapy and were rescued by exchange transfusions. Both of the children were well at age 7-years-old and one-year-old respectively In conclusion, with suspicion of fetal-maternal hemorrhage in RhD-negative pregnancies post amniocentesis, serial monitoring of indirect Coombs titer with appropriate management is mandatory.